Navigation Links
EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
Date:7/25/2012

ROCKVILLE, Md., July 25, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company, announced today the initiation of a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer. Jennifer R. Diamond, MD at the University of Colorado serves as the principal investigator for the study. The study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute.  More information about the clinical trial can be found at www.ClinicalTrials.gov.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

Jennifer R. Diamond, MD, stated, "Triple-negative breast cancer represents an aggressive breast cancer subtype which carries a high risk of developing distant metastasis.  It remains an area of unmet need in terms of effective anti-cancer agents with innovative patient selection strategies. We are encouraged by the data from the Phase 1 study of ENMD-2076 in patients with advanced solid tumors, including triple-negative breast cancer. ENMD-2076 has also demonstrated significant anti-tumor activity against preclinical models of breast cancer with more robust activity against triple-negative breast cancer alone or in combination with standard chemotherapies.  This single-agent Phase 2 study is designed to determine the activity of ENMD-2076 by the clinical benefit rate in patients with previously treated locally advanced or metastatic triple-negative breast cancer."

Ken Ren, Ph.D., EntreMed's Chief Executive Officer commented, "The development of ENMD-2076 to address the unmet medical need for an effective treatment of triple-negative breast cancer represents a part of our integrated initiatives in the clinical advancement of the ENMD-2076 oncology platform.
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
3. Psyadon Announces Positive Interim Analysis of Phase 2 Study of Ecopipam for the Treatment of Tourette Syndrome
4. Egalet Announces Issuance of U.S. Patent
5. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
6. Sancilio and Company Announces New Directors
7. Cerulean Announces First Patient Dosed in Phase 2 Study of CRLX101 in Ovarian Cancer
8. K-V Pharmaceutical Company Announces Additional Notification from NYSE Regarding Listing Criteria
9. Kraton Performance Polymers, Inc. Announces Second Quarter 2012 Earnings Release Conference Call and Webcast and 2012 Investor Day and Webcast
10. Rochester Medical Announces Third Quarter 2012 Earnings Conference Call Friday, July 27, 2012
11. Hologic Announces Pricing Of Financing In Connection With Acquisition Of Gen-Probe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014  Decision Resources Group ... (P&R) decision criteria and payer requirements in ... into each country, allow pharma to leverage ... Global market access is extremely complex, with ... requirements and challenges—and a vast variety of ...
(Date:9/23/2014)... 23, 2014 Research and Markets  has announced ... report to their offering. Diabetes is ... globe. Over 382 million people are estimated to be currently ... to 592 million by 2035. With a very high ... and India , an increasing ...
(Date:9/23/2014)... DUBLIN , September 23, 2014 /PRNewswire/ ... ) has announced the addition of the  ...  report to their offering.  ... injectable drug delivery market holds significant potential ... with vials and painful needles to the ...
Breaking Medicine Technology:Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 2Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 3Similarities In Key Global Markets Allow Pharma To Leverage Payer Value Messaging In Multiple Countries Through "Country Archetypes" Approach 4Glycated Haemoglobin (HbA1c) Testing Market 2Glycated Haemoglobin (HbA1c) Testing Market 3Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5
... February 23 BN,ImmunoTherapeutics, Inc. today provided updated ... vaccine, MVA-BN(R)-HER2, in development as,therapy of metastatic breast ... its primary endpoint with regards to safety and ... immune response was,detected in approximately 70% of evaluated ...
... An international team of,researchers has evaluated ... the knee, and the results have been ... journal "Osteoarthritis and Cartilage".,The researchers followed 376 ... treatments. After six months as well as ...
Cached Medicine Technology:BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 2BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 3New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years 2
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... cholesterol-lowering drugs while in the hospital for a hemorrhagic stroke ... than four times more likely to survive than people who ... People taking the commonly used drugs known as statins were ... to a rehabilitation facility, the study reports. When it ...
(Date:9/23/2014)... Investigators at Cincinnati Children,s Hospital Medical Center have ... gastritis (EG). The study, published in The ... that EG is a systemic disorder that has ... gastrointestinal tract, involves a series of allergy-associated-immune mechanisms ... is distinct from that of a related disorder, ...
(Date:9/23/2014)... Klose, professor of biology and a researcher in UTSA,s ... up with researchers at Ruhr University in Bochum, Germany ... findings were released this week in an article published ... Sciences . , Cholera is an acute infection caused ... with the bacterium Vibrio cholerae . An estimated ...
(Date:9/23/2014)... The community college system represents a potential source ... who will serve poor communities; however, there are ... colleges to four-year universities to medical schools. The ... recruitment, outreach and admissions practices be more inclusive ... Researchers from UCLA, UC San Francisco and San ...
(Date:9/23/2014)... "Obamacare" was signed into law in 2010 ... system since the 1960s. Designed to provide medical care ... an unwarranted intrusion into the affairs of private businesses ... healthcare systems in six Western countries, published last month ... move away from privatized medicine toward state-sponsored healthcare systems. ...
Breaking Medicine News(10 mins):Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2Health News:Medical students who attended community college likelier to serve poor communities 2Health News:Life, liberty, and the pursuit of healthcare? 2
... BIRMINGHAM, Ala. Leading high-performance computing engineers and ... University of Alabama at Birmingham (UAB) have called ... group says growing world-wide computer use puts more ... projects that are stored digitally at risk for ...
... lanes could protect more riders, researchers say , WEDNESDAY, Oct. ... and longer hospital stays, with both worsening over the past ... results of a study of biking injuries. , Chest injuries ... last five years, the study authors found. Cyclists themselves appear ...
... , MENLO PARK, Calif., Oct. 14 New Enterprise Associates, ... that Ravi Viswanathan, PhD, has been promoted to General Partner. ... on energy and growth equity information technology investments, as well ... Frank Torti, MD, to Principal. Dr. Torti joined NEA in ...
... ... industry, announced the addition of certain providers of Sistemas Medicos Nacionales, S.A. de C.V. (SIMNSA) ... ... a global health care company in the emerging medical tourism industry, announced the addition of ...
... As the leaves begin to change color and ... today announced the launch of "A BETTER BEDTIME," its 2009-2010 ... campaign is based online at the Official Pajama Program A ... , Pajama Program provides new pajamas and new books to ...
... a third of deaths, study finds, , WEDNESDAY, Oct. 14 (HealthDay ... who share a bed or sofa with a parent, and alcohol ... many of the cases, says a U.K. study. , Researchers analyzed ... between January 2003 and December 2006. Of the deaths, 54 percent ...
Cached Medicine News:Health News:UAB international conference focuses on preventing high-capacity computer data theft 2Health News:As More Cyclists Hit the Road, Serious Injuries Rise 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 2Health News:NEA Promotes Ravi Viswanathan to General Partner and Names Frank Torti to Principal Post 3Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 2Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 3Health News:Pajama Program Launches 2009-2010 Awareness & Fundraising Campaign: 'A BETTER BEDTIME' 4Health News:Shared Bed May Raise SIDS Risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: